What is Akebia Therapeutics's market cap?

Akebia Therapeutics (AKBA) has a market capitalization of $343.4M and trades on NASDAQ.

Who are Akebia Therapeutics's competitors?

Akebia Therapeutics's key competitors include Amgen Inc., Kyntra Bio, Inc. Common Stock, Revelation Biosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Akebia Therapeutics partner with?

Akebia Therapeutics's notable partners include Mitsubishi Tanabe Pharma Corporation, Vifor Pharma.

Where is Akebia Therapeutics headquartered?

Akebia Therapeutics is headquartered in United States of America and employs approximately 167 people. It has been publicly traded since 2014.

Akebia Therapeutics

AKBA

Akebia Therapeutics is a fully integrated biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients with kidney disease.

Market cap

$343.37M-64.3%

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$53.5MBeat by $1.9M EPS-$0.03Miss by $0.02

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$48.9M

EPS estimate-$0.03

Competitors

By market cap

Amgen$203.07B+25.3%

Travere Therapeutics, Inc.$5.3B+285%

Aurinia Pharmaceuticals$2.0B+63.0%

Akebia Therapeutics$343.4M-63.6%

PRO

ProKidney Corp.$316.0M-23.1%

Unicycive Therapeutics, Inc.$140.5M+134%

KYN

Kyntra Bio, Inc.$28.5M—

Revelation Biosciences, Inc.$4.1M+0.4%

By revenue growth

Travere Therapeutics, Inc.+96.0%

Aurinia Pharmaceuticals+20.6%

Amgen+9.1%

By net margin

Aurinia Pharmaceuticals99.97%+83.9pp

Amgen20.96%+3.6pp

Travere Therapeutics, Inc.-20.32%+105pp

Profile

Akebia Therapeutics is a fully integrated biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients with kidney disease. The company leverages its expertise in renal health to manage a portfolio of commercial products and a pipeline of mid-to-early stage programs targeting rare kidney diseases and other indications.

Competitive position

A leader in the kidney community with the only oral HIF-based treatment available in the U.S. for dialysis-related anemia.

GeographiesUnited States, European Union, Japan

Customer segmentsDialysis centers, Medicare beneficiaries, Nephrology clinics

Business modelProduct-based, Licensing and Royalties, R&D-driven

SuppliersActive pharmaceutical ingredient manufacturers, Contract manufacturing organizations, Clinical research organizations

CustomersDialysis providers, Wholesale distributors, Specialty pharmacies, Medicare and private insurers

CountryUnited States of America

Listed2014

Employees167.0

CEOJohn Butler

SectorHealthcare

IndustryBiotechnology

Websiteakebia.com

FilingsSEC EDGAR

Questions, answered.

What is Akebia Therapeutics's market cap?: Akebia Therapeutics (AKBA) has a market capitalization of $343.4M and trades on NASDAQ.
Who are Akebia Therapeutics's competitors?: Akebia Therapeutics's key competitors include Amgen Inc., Kyntra Bio, Inc. Common Stock, Revelation Biosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Akebia Therapeutics partner with?: Akebia Therapeutics's notable partners include Mitsubishi Tanabe Pharma Corporation, Vifor Pharma.
Where is Akebia Therapeutics headquartered?: Akebia Therapeutics is headquartered in United States of America and employs approximately 167 people. It has been publicly traded since 2014.